## What Do Patients Actually Think About "Minimally Invasive" Brain Implants?

A new study surveyed patients considering implantable [brain-computer interface](https://bciintel.com/glossary/brain-computer-interface) devices for treatment-resistant depression — and found that the industry's most-used marketing phrase, "minimally invasive," carries significant ambiguity that could directly affect informed consent. According to research published in August 2026 and reported by STAT, patients did not share a uniform interpretation of what "minimally invasive" means when applied to neural implants, raising questions about how neurotechnology companies communicate procedural risk. Anna Wexler, a medical ethics and health policy professor at the University of Pennsylvania Perelman School of Medicine, told STAT: "The term is fuzzy, problematic. Is it physical invasiveness? We're not sure, it's a fraught term." Four companies — [Synchron](https://bciintel.com/companies/synchron), [Motif Neurotech](https://bciintel.com/companies/motif-neurotech), [Precision Neuroscience](https://bciintel.com/companies/precision-neuroscience), and [Merge Labs](https://bciintel.com/companies/merge-labs) — are explicitly named in the STAT report as using the phrase "minimally invasive" prominently in their public-facing materials. For a field moving toward PMA-track clinical trials and broader patient enrollment, the disconnect between marketing language and patient understanding is not a minor communications issue — it is a regulatory and consent liability.

---

## "Minimally Invasive" Is the Industry's Most Contested Label

Scroll the website of nearly any neural interface startup today and you will encounter the same two words: minimally invasive. The phrase does real commercial work — it signals a lower risk profile than legacy deep brain stimulation surgery, differentiates newer approaches from fully intracortical systems requiring craniotomy, and implicitly reassures prospective clinical trial participants.

But as Wexler's framing makes clear, the term is doing more rhetorical lifting than definitional work. Physical invasiveness is only one axis. Patients may reasonably interpret "minimally invasive" to address cognitive risk, the permanence of the implant, the reversibility of the procedure, infection risk, or the psychological burden of living with a device embedded in or adjacent to brain tissue. None of these interpretations is wrong — and none of them is what most startup marketing teams mean when they deploy the phrase.

The companies named in the STAT report each use distinct implantation approaches. Synchron's Stentrode is an [endovascular](https://bciintel.com/glossary/endovascular) device delivered via the jugular vein, avoiding open-skull surgery entirely. Precision Neuroscience uses a thin-film [ECoG](https://bciintel.com/glossary/ecog)-style cortical surface array inserted through a small cranial slot. Motif Neurotech and Merge Labs are pursuing their own minimally invasive architectures. Each approach involves meaningfully different anatomical access, anesthesia requirements, and risk profiles — yet all claim the same "minimally invasive" label.

From a regulatory standpoint, the FDA does not define "minimally invasive" for neural devices in a way that creates enforceable advertising standards. That gap lets the label proliferate without clinical grounding.

---

## Why Treatment-Resistant Depression Is the Specific Context That Matters

The study focused on patients considering implantable devices for treatment-resistant depression — a population that is notably different from the tetraplegia and ALS patients who have been the primary participants in BCI feasibility trials to date.

This distinction has significant clinical implications. Patients with motor disabilities who enroll in intracortical BCI trials are often making decisions within a context of severe functional loss — the risk calculus involves weighing meaningful restoration of communication or motor control against surgical risk. Patients with treatment-resistant depression face a different calculus: they may retain substantial physical function, the therapeutic mechanism of a neural device is less established for psychiatric indications than for motor restoration, and the reversibility of any intervention carries heightened psychological weight.

If these patients interpret "minimally invasive" as meaning low psychological burden, minimal cognitive disruption, or easy explantability — and the clinical reality is more nuanced — the informed consent process is compromised before it begins. IRBs reviewing psychiatric BCI trials will increasingly need to scrutinize how sponsor language in recruitment materials maps to patient comprehension.

---

## Industry Trajectory and the Consent Infrastructure Problem

The BCI field is at an inflection point on patient communication. As companies move from small feasibility studies toward IDE-approved pivotal trials and eventually PMA submissions, the quality of informed consent documentation becomes a direct regulatory exposure. FDA reviewers examining human factors data and labeling will look at whether patients understood the procedural and long-term risks of the devices they enrolled to test.

The "minimally invasive" labeling issue is also a downstream product of competitive positioning. When one company claims the label, competitors face pressure to match it — creating an inflationary cycle where the phrase loses signal value entirely. This is analytically comparable to what happened with "biocompatible" as a marketing term before the FDA tightened its evidentiary requirements for biocompatibility claims.

For investors evaluating neural interface companies targeting psychiatric indications, this study is a useful calibration point: regulatory and legal risk is not limited to device performance. Patient-facing communication about procedural risk, if inconsistent with FDA-cleared labeling or IRB-approved consent forms, is an independent liability vector.

The broader BCI industry — which has built significant momentum on accessibility narratives and patient empowerment — will need to develop more precise, indication-specific language for procedural risk. That work is overdue.

---

## Key Takeaways

- A new study surveyed patients considering implantable neural devices for treatment-resistant depression and found meaningful ambiguity in how they interpret the phrase "minimally invasive"
- University of Pennsylvania medical ethicist Anna Wexler called the term "fuzzy, problematic," noting it conflates multiple distinct dimensions of invasiveness
- Synchron, Motif Neurotech, Precision Neuroscience, and Merge Labs are all identified in the STAT report as using "minimally invasive" language prominently in public materials
- Each of these companies uses a distinct implantation approach with materially different anatomical access routes and risk profiles — the shared label obscures clinically meaningful differences
- The FDA does not currently define "minimally invasive" for neural devices in an enforceable way, creating an advertising standards gap
- For companies moving toward pivotal trials and PMA submissions, patient comprehension of procedural risk is a direct regulatory and legal exposure, not merely a communications preference
- Treatment-resistant depression as a target indication creates a distinct consent dynamic compared to motor restoration applications, with different patient risk calculus and reversibility expectations

---

## Frequently Asked Questions

**What does "minimally invasive" mean for brain implants?**
There is no FDA-defined standard for "minimally invasive" as applied to neural devices. Different companies use the term to describe approaches ranging from endovascular delivery (no craniotomy required) to thin-film cortical surface implants inserted through a small skull opening. Patients may interpret the phrase to address physical trauma, cognitive risk, reversibility, or psychological burden — none of which is standardized.

**Which BCI companies use the term "minimally invasive"?**
According to the STAT report citing the underlying study, Synchron, Motif Neurotech, Precision Neuroscience, and Merge Labs all use the phrase prominently in public-facing materials. Each company uses a distinct implantation approach with different risk characteristics.

**Why does patient perception of "minimally invasive" matter for clinical trials?**
Informed consent is a core FDA and IRB requirement for any investigational device trial. If patients enroll based on a misunderstanding of what "minimally invasive" means in the context of their specific device and indication, that constitutes a consent process failure — with potential consequences for trial validity and regulatory review.

**Are psychiatric BCI trials different from motor BCI trials in terms of consent complexity?**
Yes, meaningfully so. Patients with tetraplegia or ALS enrolling in motor BCI trials are weighing surgical risk against significant functional restoration. Patients with treatment-resistant depression retain physical function and face a less-established therapeutic mechanism — making their interpretation of procedural risk language particularly consequential for consent quality.

**What should regulators do about "minimally invasive" claims in BCI marketing?**
The study and Wexler's commentary implicitly argue for clearer definitional standards — either through FDA guidance on neural device labeling or through IRB requirements that sponsor recruitment materials define the term specifically for the device and procedure in question. Until such standards exist, the label will continue to mean different things to different stakeholders.

---

*This article is based on reporting by STAT (published August 13, 2026) and covers a study in its early reporting phase. The underlying study's sample size, methodology, and peer-review status were not available in the source material accessible to this publication. Nothing in this article constitutes medical advice. Patients considering any implantable neural device should consult with their neurosurgical and medical care teams.*